MX2023007536A - Zearalenona conjugada para proteger contra micotoxicosis. - Google Patents

Zearalenona conjugada para proteger contra micotoxicosis.

Info

Publication number
MX2023007536A
MX2023007536A MX2023007536A MX2023007536A MX2023007536A MX 2023007536 A MX2023007536 A MX 2023007536A MX 2023007536 A MX2023007536 A MX 2023007536A MX 2023007536 A MX2023007536 A MX 2023007536A MX 2023007536 A MX2023007536 A MX 2023007536A
Authority
MX
Mexico
Prior art keywords
mycotoxicosis
zearalenone
conjugated
protect against
damage
Prior art date
Application number
MX2023007536A
Other languages
English (en)
Inventor
Maarten Hendrik Witvliet
Ruud Philip Antoon Maria Segers
Sietske Kooijman
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2023007536A publication Critical patent/MX2023007536A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Insulated Conductors (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de zearalenona conjugada (ZEA) en un método para proteger a un animal contra la micotoxicosis inducida por ZEA, en particular para proteger contra el aumento de peso disminuido, daño renal, daño hepático y daño a un órgano reproductor.
MX2023007536A 2020-12-22 2021-12-21 Zearalenona conjugada para proteger contra micotoxicosis. MX2023007536A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20216328 2020-12-22
PCT/EP2021/086945 WO2022136343A1 (en) 2020-12-22 2021-12-21 Conjugated zearalenone to protect against mycotoxicosis

Publications (1)

Publication Number Publication Date
MX2023007536A true MX2023007536A (es) 2023-07-10

Family

ID=73856714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007536A MX2023007536A (es) 2020-12-22 2021-12-21 Zearalenona conjugada para proteger contra micotoxicosis.

Country Status (9)

Country Link
US (1) US20240024496A1 (es)
EP (1) EP4267187A1 (es)
JP (1) JP2023554137A (es)
CN (1) CN116710144A (es)
AU (1) AU2021406283A1 (es)
CA (1) CA3202786A1 (es)
CL (1) CL2023001819A1 (es)
MX (1) MX2023007536A (es)
WO (1) WO2022136343A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397597A (zh) * 2016-09-14 2017-02-15 湖南沙博安科技有限责任公司 一种抗f2卵黄抗体的制备方法

Also Published As

Publication number Publication date
CA3202786A1 (en) 2022-06-30
EP4267187A1 (en) 2023-11-01
JP2023554137A (ja) 2023-12-26
AU2021406283A1 (en) 2023-06-22
CL2023001819A1 (es) 2024-03-08
WO2022136343A1 (en) 2022-06-30
CN116710144A (zh) 2023-09-05
US20240024496A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
PH12021550805A1 (en) Methods and Compositions for Editing RNAs
MX2021012645A (es) Metodos y composiciones para editar acidos ribonucleicos (arn).
AU2018320870A1 (en) RNA targeting methods and compositions
EP3282448A3 (en) Compression of decomposed representations of a sound field
CU20190076A7 (es) Combinación fungicida sdhi
CY1108344T1 (el) Φορεις εκφρασης που περιεχουν τον mcmv ie2 υποκινητη
MX344513B (es) Procedimiento para tratar infecciones fungicas, composiciones fungicidas y su uso.
DE60239831D1 (de) Auf trans-splicing basierende amplifikationsvectoren
EA202090684A1 (ru) Цельнооболочечный безопасный снаряд, в частности, для универсальных использований
MX2023007536A (es) Zearalenona conjugada para proteger contra micotoxicosis.
ECSP21053728A (es) Mezcla fungicida
CN104924392A (zh) 一种高效的木材防腐剂
MX2022011779A (es) Combinacion herbicida.
MX2020009478A (es) Compuestos y sus usos para tratar tumores en un paciente.
MX2021015837A (es) Desoxinivalenol conjugado para proteger contra micotoxicosis.
MX2023007538A (es) Fumonisina conjugada para proteger contra la micotoxicosis.
EA201001727A1 (ru) Устройство и способ для обработки заготовок взрывным формованием
MX2023007535A (es) Toxina t-2 conjugada para proteger contra la micotoxicosis.
KR20230050729A (ko) 마그네틱 케이스
Webber A Visitation of God: Northern Civilians Interpret the Civil War
WO2007016680A3 (en) Phage-display plant defense peptides directed against phakopsora pachyrhizi and uromyces appendiculatus
MX2020013201A (es) Nuevos usos de 9-(3-desoxi-beta-d-ribofuranosil)adenina.
Sood et al. Down-regulation of cyclooxygenase-2 by the carboxyl tail of the angiotensin II type 1 receptor.
CO2023008508A2 (es) Composición fungicida de ditiocarbamato
王秀凤 Yesterday Once More